Sclerosing Agents For the Prevention of Recurrent Malignant Pleural Effusion

Sclerosol® Intrapleural Aerosol - Product 1680

Sclerosol® Intrapleural Aerosol is FDA approved for the treatment of Recurrent Malignant Pleural Effusion in symptomatic patients.

Containing 4 grams of asbestos-free, brucite-free pharmaceutical grade sterile talc powder, Sclerosol® Intrapleural Aerosol is packed in a single use canister and has a 2.5 year shelf life.

Please refer to package insert for Sclerosol® Intrapleural Aerosol for information relating to indications, administration and clinical pharmacology.

Sterile Talc Powder™ - Product 1690

FDA approved Sterile Talc Powder™, administered intrapleurally via chest tube, is indicated to decrease the Recurrence of Malignant Pleural Effusions in symptomatic patients.

Containing 5 grams of asbestos-free, brucite-free pharmaceutical grade sterile talc of a controlled particle size, Sterile Talc Powder™ is conveniently packaged in a 100 ml vial and has a 2 year shelf life.

Please refer to package insert for Sterile Talc Powder™ for information relating to indications, administration and clinical pharmacology.

What is Malignant Pleural Effusion?

Malignant Pleural Effusion (MPE) results from an accumulation of fluid in the pleural space, the area between the layer lining the chest cavity (parietal pleura) and the membrane covering the lungs (visceral pleura). The condition occurs in a variety of disease states, including pneumonia and congestive heart failure. It is a common complication of malignant disease, particularly in patients with advanced cancer. MPE results from an increase in capillary permeability caused by metastases to the pleural membranes or from impairment of lymphatic drainage by the tumor. The three cancers most commonly associated with MPE are breast, lung and lymphoma, though almost all malignancies can cause MPE. Symptoms include chest pain, dyspnea, and cough. Most patients diagnosed with MPE are terminal. Control of MPE can greatly improve the patient's quality of life.

What is the most effective treatment for MPE?

The most effective treatment is the use of a sclerosing agent. Bleomycin, Tetracycline and Doxycycline have been used in the past, but research has shown sterile talc to be the most effective and affordable treatment. Talc irritates the visceral pleura, causing it to adhere to the parietal pleura and preventing further accumulation of fluid.

Sclerosol® Intrapleural Aerosol (Product No. 1680) introduces sterile talc into the pleural space with an aerosolized application process whereas Sterile Talc Powder™ (Product No. 1690) is administered intrapleurally via chest tube. Research has shown sterile talc to be a clean and effective treatment that causes little discomfort for patients.